This content was current as of the date it was released. In science and medicine, information is constantly changing and may become out-of-date as new data emerge.
Have you relapsed on, or become refractory to a BTK inhibitor drug such as ibrutinib, or the BCL2 inhibitor drug venetoclax? These drugs have radically improved how CLL is treated. However, when patients relapse or become refractory to these treatments, the approved PI3-kinase inhibitors duvelisib or idelalisib, and the still experimental umbralisib, offer a potent and potentially helpful third option. Side effects of PI3Ks have made some patients apprehensive. However, if properly managed, many CLL patients could reap benefits from these effective medications. Frontload your knowledge about PI3K inhibitors! Dr. Ian Flinn will present at Revisiting PI3K Inhibitors for the Treatment of CLL: Are They Living Up to Their Promise? on Thursday, August 26th at 10:00 AM PT, 11:00 AM MT, 12:00 PM CT, 1:00 PM ET.
Big News in Prevention of COVID-19 Infection from Regeneron: FDA Okays Regeneron COVID-19 Antibody as Preventive for Chronic Lymphocytic Leukemia (CLL) and Other Immunocompromised Patients
Immunocompromised patients, such as those with CLL, can now receive the antibodies REGEN-COV (casirivimab and imdevimab) if they are at risk for severe disease due their impaired immunity and have been exposed to COVID-19 or are at high risk of exposure. This is the therapeutic combination that probably saved President Trump’s life. It is no longer a requirement to test positive for COVID-19 to receive the antibodies. This new indication is taken directly from the July 30th, 2021, Emergency Use Authorization (EUA) paperwork. Learn more here.
From the United Kingdom: Freedom Day’s Winners and Losers
The relaxing of COVID-19 restrictions does not guarantee safety for the immunocompromised. In fact, the more “freedom” from masking and social distancing the community enjoys, the more locked down the vulnerable become. No one could better express the negative consequences for the immunocompromised in both medical and psychological terms than our friend, fellow CLL patient and advocate and longtime CLL Society international patient advocate member, Nick York of CLLAN and Leukaemia Care of the UK. Read Nick’s News 4 interview Freedom Day’s Winners and Losers.
Ryan Mitchell’s 79-mile Bike Ride for CLL Society!
We are always excited to see the creative ways our community stands up to support us so we can support YOU. On August 15th Ryan Mitchell will be participating in the Portland Century Ride, cycling 79 miles himself, and raising funds for the CLL Society. Please consider supporting Ryan’s efforts by donating to his fundraising page. We are so grateful to have strong supporters on our team. Thank you, Ryan Mitchell!
At the annual meeting of the American Society of Hematology (ASH) 2020, Dr. John Pagel of the CLL Society Board of Directors interviewed Dr. Peter Hillmen, Professor of Experimental Hematology at the University of Leeds in the United Kingdom. They discussed updates to the phase II CLARITY trial which has been evaluating the efficacy of combination ibrutinib and venetoclax in patients with relapsed/refractory CLL.
CLL Society has partnered with Clinical Care Options to develop an educational activity for healthcare providers who treat patients with CLL. This program features expert insight commentaries, an Interactive Treatment Decision Support Tool, and a series of micro education modules. Not only will it help improve CLL care for healthcare providers, it can also help empower and engage patients to become informed participants in shared decision-making. Learn more about “Optimizing Decision-Making in CLL in an Era of Novel Agents” and consider sharing with your healthcare providers.
The new 1-hour online educational session, Navigating Treatment with BTK Inhibitors led by Dr. Matthew Davids, Associate Professor of Medicine, Harvard Medical School, Associate Director, Center for Chronic Lymphocytic Leukemia, Dana-Farber Cancer Institute is now available to watch on-demand. Hear a CLL patient’s perspective on the latest findings on long-term efficacy of BTK inhibitors, side-effect management, and adopting healthy lifestyles to improve outcomes.
This educational module is the first in a series specifically designed to help patients and caregivers understand the available treatment options for CLL across the continuum of care, learn about the details of BTK inhibitor treatments, and confidently talk with your doctors and other clinicians to align your goals and priorities for care.
CLL Society Support Group Meetings Coming Up!
CLL Society Support Group meetings have moved to a virtual platform for most locations due to the threat of coronavirus. Support group members will receive an invitation to register for the meeting from the support group facilitator. If you are new to the group, please contact the RSVP email for the Support Group in your region. Once it is safe again, we will resume in-person meetings.
Visit the individual event listings on our website for the most up-to-date information on all CLL Society Support Group meetings.